ES2111769T3 - Nuevos usos de il-10. - Google Patents

Nuevos usos de il-10.

Info

Publication number
ES2111769T3
ES2111769T3 ES93920050T ES93920050T ES2111769T3 ES 2111769 T3 ES2111769 T3 ES 2111769T3 ES 93920050 T ES93920050 T ES 93920050T ES 93920050 T ES93920050 T ES 93920050T ES 2111769 T3 ES2111769 T3 ES 2111769T3
Authority
ES
Spain
Prior art keywords
combination
another embodiment
antibodies against
production
inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93920050T
Other languages
English (en)
Spanish (es)
Inventor
Robert Coffman
Vries Jan E De
Waal Malefyt Rene De
Fiona Powrie
Donna Rennick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/932,900 external-priority patent/US5368854A/en
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2111769T3 publication Critical patent/ES2111769T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
ES93920050T 1992-08-20 1993-08-18 Nuevos usos de il-10. Expired - Lifetime ES2111769T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/932,900 US5368854A (en) 1992-08-20 1992-08-20 Use of IL-10 to treat inflammatory bowel disease
US93341992A 1992-08-21 1992-08-21
US93395092A 1992-08-21 1992-08-21
US93346292A 1992-08-21 1992-08-21

Publications (1)

Publication Number Publication Date
ES2111769T3 true ES2111769T3 (es) 1998-03-16

Family

ID=27506019

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93920050T Expired - Lifetime ES2111769T3 (es) 1992-08-20 1993-08-18 Nuevos usos de il-10.

Country Status (22)

Country Link
EP (2) EP0671933B1 (OSRAM)
JP (1) JP3494647B2 (OSRAM)
KR (1) KR0170037B1 (OSRAM)
CN (1) CN1090204A (OSRAM)
AT (1) ATE162947T1 (OSRAM)
AU (1) AU680628B2 (OSRAM)
CA (1) CA2142861C (OSRAM)
CZ (1) CZ283488B6 (OSRAM)
DE (1) DE69316921T2 (OSRAM)
DK (1) DK0671933T3 (OSRAM)
ES (1) ES2111769T3 (OSRAM)
FI (1) FI950697L (OSRAM)
GR (1) GR3026635T3 (OSRAM)
HU (1) HU220103B (OSRAM)
IL (1) IL106725A (OSRAM)
MX (1) MX9305054A (OSRAM)
MY (1) MY111402A (OSRAM)
PL (1) PL307566A1 (OSRAM)
RU (1) RU2120802C1 (OSRAM)
SK (1) SK21195A3 (OSRAM)
TW (1) TW243415B (OSRAM)
WO (1) WO1994004180A2 (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017773A2 (en) * 1993-02-01 1994-08-18 Université Libre de Bruxelles Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
CZ1497A3 (en) * 1994-07-05 1997-05-14 Steeno Res Group As Polypeptide, its use and pharmaceutical composition based thereon, a nucleotide sequence and antibody
JPH11501506A (ja) 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター キメラ型サイトカインおよびその利用
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
EP0756871A1 (en) * 1995-08-01 1997-02-05 Institut Pasteur Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
EP0901375A1 (en) * 1996-04-17 1999-03-17 Patrick Thomas Prendergast Dhea combination therapy
WO1998027997A1 (en) * 1996-12-20 1998-07-02 Magainin Pharmaceuticals Inc. A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
AU5221998A (en) * 1997-04-17 1998-11-13 Patrick T. Prendergast Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US6001651A (en) * 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
EP1123314B1 (en) * 1998-10-20 2004-02-18 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Use of a cytokine-producing lactococcus strain to treat colitis
RU2140283C1 (ru) * 1998-12-15 1999-10-27 Товарищество с ограниченной ответственностью "Биотех" Фармацевтический препарат на основе интерлейкина-2 (варианты)
MXPA01008142A (es) 1999-02-10 2003-07-21 Welfide Corp Compuestos de amida, y uso medicinal de los mismos.
JP2003518627A (ja) * 1999-12-03 2003-06-10 バクスター・インターナショナル・インコーポレイテッド 自動イムノアッセイシステムを用いる使用のための発熱性試験
KR20020091170A (ko) * 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
US6797263B2 (en) 2000-05-12 2004-09-28 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
RU2196605C2 (ru) * 2000-12-07 2003-01-20 Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера Способ получения растворимых конъюгатов биологически активных веществ
RU2202363C2 (ru) * 2001-04-09 2003-04-20 Ершов Феликс Иванович Способ определения чувствительности живого организма и/или его клеток к воздействию вещества, поля или комбинации веществ и/или полей
US20040197304A1 (en) * 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
PE20090047A1 (es) * 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
AR050044A1 (es) 2004-08-03 2006-09-20 Novartis Ag Anticuerpo especifico de il-4
EP2270131A1 (en) 2005-05-31 2011-01-05 The Iams Company Feline probiotic lactobacilli
PL1885383T3 (pl) 2005-05-31 2017-06-30 Iams Europe B.V. Kocie probiotyczne bifidobakterie
ES2399987T3 (es) * 2005-10-03 2013-04-04 Actogenix N.V. Uso de una cepa de levadura recombinante que produce un compuesto antiinflamatorio en la fabricación de un medicamento para tratar colitis
CA2664304C (en) * 2006-09-28 2017-08-22 Schering Corporation Use of pegylated il-10 to treat cancer
CN101711158A (zh) 2007-02-01 2010-05-19 爱默思公司 使用葡萄糖抗代谢物、鳄梨或鳄梨提取物减轻哺乳动物炎症和应激反应的方法
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
HK1215681A1 (zh) * 2013-04-18 2016-09-09 Armo Biosciences, Inc. 使用白细胞介素-10治疗疾病和病症的方法
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
RS57974B1 (sr) 2013-07-18 2019-01-31 Xalud Therapeutics Inc Sastavi za lečenje inflamatornog oboljenja zglobova
AU2014311432A1 (en) 2013-08-30 2016-03-03 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
ES3039640T3 (en) 2015-08-25 2025-10-23 Armo Biosciences Inc Methods of using interleukin-10 for treating diseases and disorders
CN114349858B (zh) * 2022-01-26 2022-07-01 优睿赛思(武汉)生物科技有限公司 抗人白介素-10高亲和力兔单克隆抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
DK0567576T3 (da) * 1991-01-16 1995-06-12 Schering Corp Behandling af neoplastiske sygdomme med interleukin-10
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair

Also Published As

Publication number Publication date
AU680628B2 (en) 1997-08-07
JPH08500362A (ja) 1996-01-16
CA2142861A1 (en) 1994-03-03
CZ44195A3 (en) 1995-10-18
HU220103B (hu) 2001-10-28
DE69316921D1 (de) 1998-03-12
IL106725A (en) 2000-12-06
WO1994004180A3 (en) 1994-06-09
WO1994004180A2 (en) 1994-03-03
EP0671933A1 (en) 1995-09-20
IL106725A0 (en) 1993-12-08
JP3494647B2 (ja) 2004-02-09
FI950697A7 (fi) 1995-04-07
GR3026635T3 (en) 1998-07-31
FI950697A0 (fi) 1995-02-16
EP0801951A2 (en) 1997-10-22
HUT70976A (en) 1995-11-28
CA2142861C (en) 2000-08-15
RU2120802C1 (ru) 1998-10-27
KR0170037B1 (ko) 1999-02-01
EP0801951A3 (en) 1998-05-20
PL307566A1 (en) 1995-05-29
CN1090204A (zh) 1994-08-03
HK1004326A1 (en) 1998-11-20
AU5010893A (en) 1994-03-15
SK21195A3 (en) 1996-10-02
KR950702841A (ko) 1995-08-23
EP0671933B1 (en) 1998-02-04
RU95108330A (ru) 1996-11-27
ATE162947T1 (de) 1998-02-15
DK0671933T3 (da) 1998-09-23
FI950697L (fi) 1995-04-07
DE69316921T2 (de) 1998-06-04
MX9305054A (es) 1994-02-28
MY111402A (en) 2000-04-29
HU9500467D0 (en) 1995-04-28
CZ283488B6 (cs) 1998-04-15
TW243415B (OSRAM) 1995-03-21

Similar Documents

Publication Publication Date Title
ES2111769T3 (es) Nuevos usos de il-10.
IT8620207A0 (it) Procedimento per indurre protoginia in piante di zea mays e relativo zea mays protogino.
MX9405383A (es) Imidazo(4,5-c) piridin-4-aminas.
NO960743L (no) Cellulære preparater, deres fremstilling og terapeutiske anvendelse
NO326660B1 (no) Imidazolyl-cykliske acetal forbindelser, farmasøytiske sammensetninger inneholdende disse forbindelser og anvendelse av forbindelsene
ES2087061T3 (es) Utilizacion de ribosido o ribotido de aica para la fabricacion de un medicamento contra la crisis cardiaca o el infarto de miocardio en los pacientes que sufren de ateroesclerosis.
ES2171268T3 (es) Formulaciones de tramadol de multiples unidades.
NO981746D0 (no) Utlevering av biologisk aktive polypeptider
PE20040751A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE DOSIS BAJAS DE UN INHIBIDOR DEL TNFalfa HUMANO
ATE140483T1 (de) Natürlicher killerzellen-stimulationsfaktor
ES2054708T3 (es) Gen de resistencia frente a fosfinotricina, activo en plantas y su utilizacion.
MX9703621A (es) Nuevos derivados aminoacidos con actividad mejorada para la resistencia a drogas multiples.
DE59007178D1 (de) Verwendung alkylierter Polyethylenimine als gallensäureadsorbierende Arzneimittel sowie pharmazeutische Präparate.
NO983372L (no) Modulering av TH1/TH2 cytokinekspresjon av Ribavirin og Ribavirinanaloger i aktiverte T-lymfocytter
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
AR008847A1 (es) Construcciones de acidos nucleicos para la expresion regulada de un transgen en una celula hospedante para uso en la terapia fenica y lamanipulacion genetica, una celula aislada que los comprende y una composicion farmaceutica
ES2103854T3 (es) Peptidos con actividad organo protectiva, procedimiento para la preparacion de los mismos y su utilizacion en la terapia.
ECSP045297A (es) Inhibidores de la microglía para interrumpir reacciones inmunes asociadas con interleucina 12 y ifn?
ES2032922T3 (es) Empleo de los paf-aceter antagonicos para la fabricacion de un medicamento y procedimiento para determinar la eficacia de los mismos.
ES2036526T3 (es) Composiciones de interferon.
BR8907708A (pt) Composicoes farmaceuticas compreendendo calcitonina para administracao intranasal e uma unidade de aerossol para administracao das mesmas
MX9204613A (es) Nitratos organicos, procedimientos para su preparacion y su uso en el tratamiento de enfermedades cardiovasculares
DK1017667T3 (da) 2-amino-6-methyl-7-acetyltetralin og farmaceutiske præparater til forebyggelse og terapeutisk behandling af inflammatoriske og/eller autoimmune patalogier
IT8021550A0 (it) Derivati adenosinici ad attivita'antinfiammatoria ed analgesica e composizioni terapeutiche che licontengono come principio attivo.
Sredni-Kenigsbuch et al. Neutrophils augment the release of TNFα from LPS-stimulated macrophages via hydrogen peroxide

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 671933

Country of ref document: ES